17 Aug Sandoz and Novartis: Warning about small increased risk of oral clefts following use in the first 12 weeks of pregnancy
Posted at 12:45h
in
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of an increased risk of cleft lip and/or cleft palate following the use of ZOFRAN® (ondansetron) during the first 12 weeks of pregnancy.
2020 Jun
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
12/06/2020
File Type:
pdf
Category:
Communication To Health Care Professionals